Literature DB >> 19619253

Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas.

Atsunori Tsuchiya1, Hiroteru Kamimura, Masaaki Takamura, Satoshi Yamagiwa, Yasunobu Matsuda, Yoshinobu Sato, Minoru Nomoto, Takafumi Ichida, Yutaka Aoyagi.   

Abstract

AIM: Hepatic stem cells are capable of dramatically changing and differentiating to form mature hepatocytes in acute and chronically damaged livers; however, the clinicopathological characteristics of these heterogeneous cell populations have not been sufficiently analyzed.
METHODS: In this study, cells in tissue sections from 12 cases of acute damaged livers and 31 cases of hepatocellular carcinomas (HCC), and the surrounding chronically damaged liver tissues, were analyzed by immunohistochemistry using the previously reported hepatic stem/progenitor cell marker CD133 (AC133) and the neural cell adhesion molecule (NCAM) marker.
RESULTS: In both the acute and chronically damaged livers, CD133(+) cells and NCAM(+) cells were present in ductular reactions (DR), which include hepatic stem/progenitor cells, and became more apparent in proportion to the degree of fibrosis or histological damage. Analysis of their distribution and morphological similarities revealed that the NCAM(+) cell population included cells that were closer to, and morphologically more similar to, hepatocytes than were CD133(+) cells. Analysis of HCC using these markers revealed that 9.7% of HCC expressed NCAM (two cases had abundant NCAM(+) cells), while CD133(+) HCC were not detected.
CONCLUSION: These results suggest that CD133 and NCAM can be employed to enrich for hepatic stem/progenitor cells and that DR can be distinguished in greater detail using these markers. NCAM(+) HCC were detected, but their function remains unresolved. Expression of CD133, a potent stem cell marker, may be extremely rare in the common human HCC examined.

Entities:  

Year:  2009        PMID: 19619253     DOI: 10.1111/j.1872-034X.2009.00559.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  13 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.

Authors:  Chen Zhong; Jin-Dao Wu; Ming-Ming Fang; Li-Yong Pu
Journal:  Tumour Biol       Date:  2015-04-29

3.  Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice.

Authors:  Atsunori Tsuchiya; Michitaka Imai; Hiroteru Kamimura; Masaaki Takamura; Satoshi Yamagiwa; Tatsuki Sugiyama; Minoru Nomoto; Toshio Heike; Takashi Nagasawa; Tatsutoshi Nakahata; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2012-06-05       Impact factor: 3.199

Review 4.  Clinical implications of cancer stem cell biology in hepatocellular carcinoma.

Authors:  Junfang Ji; Xin Wei Wang
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

5.  Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.

Authors:  George S Wilson; Zenan Hu; Wei Duan; Aiping Tian; Xin M Wang; Duncan McLeod; Vincent Lam; Jacob George; Liang Qiao
Journal:  Stem Cells Dev       Date:  2013-06-08       Impact factor: 3.272

6.  Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor.

Authors:  Tsutomu Fujii; Bryan C Fuchs; Suguru Yamada; Gregory Y Lauwers; Yakup Kulu; Jonathan M Goodwin; Michael Lanuti; Kenneth K Tanabe
Journal:  BMC Gastroenterol       Date:  2010-07-09       Impact factor: 3.067

7.  Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA).

Authors:  Rui Liu; Yuan Shen; Kejun Nan; Baibing Mi; Tao Wu; Jinyue Guo; Miaojing Li; Yi Lv; Hui Guo
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

Review 8.  Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases.

Authors:  Atsunori Tsuchiya; Yuichi Kojima; Shunzo Ikarashi; Satoshi Seino; Yusuke Watanabe; Yuzo Kawata; Shuji Terai
Journal:  Inflamm Regen       Date:  2017-07-03

9.  Early Detection of Hepatocellular Carcinoma Recurrence Using the Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein.

Authors:  Toru Setsu; Atsunori Tsuchiya; Takayuki Watanabe; Takuro Nagoya; Satoshi Ikarashi; Kazunao Hayashi; Junji Yokoyama; Satoshi Yamagiwa; Shuji Terai
Journal:  Case Rep Gastroenterol       Date:  2017-03-21

10.  Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma.

Authors:  Jong Jin Sung; Sang Jae Noh; Jun Sang Bae; Ho Sung Park; Kyu Yun Jang; Myoung Ja Chung; Woo Sung Moon
Journal:  J Pathol Transl Med       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.